PON1 and chronic myelogenous leukemia, BCR-ABL1 positive: The neurotoxicity of CML (250 μg) was ameliorated by a co-treatment with CIGB-258 (1 μg) by inhibiting the amyloidogenesis of HDL and recovery of HDL3-associated PON activity.